Paratek Pharmaceuticals Opens New Corporate Headquarters in Boston
News Jul 24, 2015
Paratek Pharmaceuticals, Inc. has opened its new corporate headquarters in Boston at 75 Park Plaza.
"This move comes at an important time for Paratek, as we have recently initiated a global Phase 3 program for our lead antibiotic compound, omadacycline. With two important products in Phase 3 clinical studies, we are now preparing for the next phase of our growth as a biopharmaceutical company," said Michael Bigham, Chairman and Chief Executive Officer, Paratek. "The Company takes pride in its origins as a Boston-based biopharmaceutical company, and we look forward to our continued growth here in Boston."
The address of the new headquarters is 75 Park Plaza, 4th floor, Boston, MA 02116. Paratek was previously located at 75 Kneeland Street in Boston. In June Paratek opened a second office location in the Philadelphia area.
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Medherant Expands Team with Appointment of David Davies as Head of DevelopmentNews
Medherant Ltd, a leader in next-generation transdermal drug delivery, is pleased to announce the appointment of a new senior executive, David Davies, as Head of Development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018